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ABSTRACT
Radiotherapy (RT) remains a standard therapeutic modality for breast cancer
patients. However, intrinsic or acquired resistance limits the efficacy of RT. Here, we
demonstrate that CHK1 inhibitor AZD7762 alone significantly inhibited the growth
of radioresistant breast cancer cells (RBCC). Given the critical role of ATR/CHK1
signaling in suppressing oncogene-induced replication stress (RS), we hypothesize
that CHK1 inhibition leads to the specific killing for RBCC due to its abrogation in the
suppression of RS induced by oncogenes. In agreement, the expression of oncogenes
c-Myc/CDC25A/c-Src/H-ras/E2F1 and DNA damage response (DDR) proteins ATR/
CHK1/BRCA1/CtIP were elevated in RBCC. AZD7762 exposure led to significantly
higher levels of RS in RBCC, compared to the parental cells. The mechanisms by which
CHK1 inhibition led to specific increase of RS in RBCC were related to the interruptions
in the replication fork dynamics and the homologous recombination (HR). In summary,
RBCC activate oncogenic pathways and thus depend upon mechanisms controlled by
CHK1 signaling to maintain RS under control for survival. Our study provided the first
example where upregulating RS by CHK1 inhibitor contributes to the specific killing
of RBCC, and highlight the importance of the CHK1 as a potential target for treatment
of radioresistant cancer cells.

INTRODUCTION

predictive factors that could help to define the subgroups
of patients for whom aggressive local therapeutic option is
not needed due to their intrinsic resistance, and determine
the subgroups of patients who will really benefit from new
treatment strategies after failure of RT.
Ionizing radiation (IR) kills cells via causing multiple
forms of DNA damage. DNA double strand breaks (DSBs)
represent the most dangerous type of DNA damage and is
a determining factor of cellular radiosensitivity [1]. DSBs
can also be caused by other sources, such as environmental

Radiotherapy (RT) is an effective and commonly
employed treatment in the management of more than half
of human malignancies, and remains a standard therapeutic
modality for breast cancer patients. However, tumors can
be intrinsically resistant to RT or develop adaptive response
and become resistant. Thus, the curative potential of RT
is limited by the radioresistance of the tumor cells. The
challenges in breast cancer management are to determine
www.impactjournals.com/oncotarget
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mutagens, chemotherapeutic drugs and any situations
causing replication stress (RS) that is defined as slowing or
stalling of replication fork progression and/or subsequent
fork collapse. One major source causing RS is oncogene
expression [2, 3]. DNA damage response (DDR) prevents the
cells from lethality due to the damaged DNA via activation
of cell cycle checkpoints, promotion of DNA repair,
alteration of transcription and triggering apoptosis [4, 5].
Ataxia telangiectasia, and rad3-related (ATR) kinase and
its downstream factor CHK1 are core elements of the DDR
during replication stress. CHK1 is phosphorylated on serine
317 and serine 345, respectively, by ATR, and these sites are
required for the ability of CHK1 to amplify the signal by
phosphorylating several additional targets [6, 7]. ATR/CHK1
signaling is important for the cells survival in response to
DNA damage agents that cause RS.
ATR/CHK1 is also essential for cell proliferation or
viability in the absence of exogenous DNA damage [5, 8–11].
CHK1 promotes replication and transformation in an animal
model by limiting oncogene-induced replication stress [12].
In this context, the generation of DNA damage, particularly
DSBs induced by oncogenic stress, is suppressed by CHK1
in order to provide the advantage of cell survival. Molecular
mechanisms by which ATR/CHK1 maintain viability of
cells and suppress oncogene-induced transformation in the
absence of exogenous DNA damage are not fully understood.
The role of ATR/CHK1 in inhibiting abnormal initiation and
elongation of DNA replication [13– 15] and maintaining
the stability of replication forks [16–18] and promoting
replication fork restart could be important mechanisms [19].
Moreover. The role of ATR/CHK1 in homologous
recombination (HR) could be also involved since HR is one of
important mechanism that repair RS-induced DSBs [20–22].
Thus, ATR/CHK1 signaling is not only critical for the cell
survival in the presence of exogenous DNA damage but also
essential for cell survival in the absence of exogenous DNA
damage, particularly during tumor development.
CHK1 inhibitors have been developed for clinical
use, principally with the idea that they would be used to
enhance killing of tumor cells by cytotoxic drugs or by
radiation, via blocking cell cycle checkpoints, especially in
p53 deficient cells [23–26]. Recent studies strongly suggest
that sensitization activity of CHK1 inhibitor to IR and/or
chemotherapeutic drugs is through a variety of mechanisms,
such as inhibition of HR and/or interruption of replication
fork stability [27–29]. In addition, although a previous
report indicated that CHK1 inhibitor, as a single agent, has
none or minimal role in antitumor activity [30], emerging
data revealed that CHK1 inhibitor alone can specifically
kill some tumor cells [31, 32]. However, the molecular
mechanisms controlling the anti-tumor activity of CHK1
inhibitor have not been identified.
The goal of our study is to define the differences of
DDR between radiosensitive cells and radioresistant breast
cancer cells (RBCC), and to seek for a better regimen
targeting the radioresistance. Here, we report that oncogene
www.impactjournals.com/oncotarget

proteins c-Myc/CDC25A/c-Src/H-ras/E2F1 and DDR
proteins ATR/CHK1/BRCA1/CtIP are highly expressed
in RBCC. CHK1 inhibition specifically targets RBCC via
enhancing RS levels. Our studies, for the first time, apply
the concept that increase RS by CHK1 inhibition can target
RBCC. Our findings may be more broadly applicable for
targeting cancers with similar characteristic as RBCC by
CHK1 inhibitors.

RESULTS
CHK1 inhibitor, as a single agent, significantly
suppresses the growth of cancer cells but fails to
sensitize RBCC to IR
Given that CHK1 inhibitor has been reported to
sensitize the advanced pancreatic cancer cells to IR [28],
CHK1 inhibition could sensitize the RBCC to IR. In order
to test this hypothesis, human breast cancer cells MCF-7
and MDA-MB-231, and their corresponding IR -selected
radioresistant cells (MCF-7/C6 and MDA-MB-231 FIR)
were used [33, 34]. MCF-7 and MDA-MB-231 cells
carry wild type p53 and mutant p53, respectively. We first
detected the radio-sensitization activity of CHK1 inhibitor
AZD7762 using colony formation assay. As we expected,
MCF-7/C6 cells are more resistant to IR, compared to their
own parental cells (Figure 1A). However, surprisingly,
AZD7762 failed to sensitize MCF-7/C6 cells to IR
(Figure 1B). Strikingly, we found that CHK1 inhibitor alone
caused a dramatic suppression on cell growth in MCF-7/
C6 compared to MCF-7 cells (Figure 1C). This result was
further confirmed by a second CHK1 inhibitor LY2603618
(Figure S1A). Through measuring sub-G1 cells by flow
cytometry, we determined the status of apoptosis. In both
MCF-7 and MCF-7/C6, a pattern can be seen where there
is a shift in the percentage of sub-G1 cells from viable to
apoptosis as the dose escalates (Figure S2A, S2B). However,
the percentage of sub-G1 phase cells is significantly higher
in MCF-7/C6 cells, compared to control cells at the same
conditions. This result was further confirmed by detecting
the most optimal biomarkers of apoptosis, such as cleaved
caspase 7, 9 and cleaved PARP proteins (Figure S2C).
Thus, apoptosis is involved in cell killing induced by CHK1
inhibition. However, we cannot exclude the possibility that
other mechanisms of cell death are also involved, such as
mitotic catastrophe.
The result that CHK1 inhibitor alone caused a
dramatic suppression on MCF-7/C6 cells was further
supported by the second cell line MDA-MB-231 FIR
(Figure 1D–1F) but the effect of CHK1 inhibition on cell
growth is much less significant in MDA-MB-231 FIR
(Figure 1F), compared to MCF-7/C6 cells (Figure 1C).
Next, in order to further confirm the antitumor activity
of CHK1 inhibitor in RBCC in vivo, we determined the
efficacy of AZD7762 using tumor xenograft models.
Groups of tumor-bearing mice were given CHK1 inhibitor
34689
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Increased expression of oncogene and DDR
proteins are induced in RBCC

or DMSO i.p. daily for 3 days. Two cycles of CHK1
inhibitor were given. For MCF-7/C6 xenografts, the data
was analyzed as the time for the tumor volume to reach
1500 mm3 (p < 0.0001) (Figure 1G, left panel). Clearly,
there is a significant delay of tumor growth in the group
with inhibitor treatment. Thus, the tumors growth is
suppressed when CHK1 inhibitor is administrated in
radioresistant MCF-7/C6 xenograft. In contrast, for MCF-7
xenograft, the time for tumor volume to reach 1500 mm3 is
similar in the group with or without treatment (Figure 1G,
right panel). Taken together, our results described in Figure
1 suggest that CHK1 inhibitor AZD7762, as a single agent,
can significantly block the tumor growth of RBCC in both
in vitro and in vivo assays.

We next ascertained the potential molecular
mechanisms by which CHK1 inhibitor specifically targets
RBCC. Given that oncogenes can be induced in response to
IR [35] and ATR/CHK1 suppresses oncogenic stress [12],
we hypothesized that CHK1 inhibition upregulates RS,
therefore leading to specific cell killing of RBCC . In order
to test this hypothesis, we first determined the expression of
oncogene proteins that have been reported to cause RS [2, 3].
Notably, oncogenes c-Myc/CDC25A/c-Src/H-Ras/E2F1
are induced in MCF-7/C6 and MDA-MB-231-FIR cells
compared to MCF-7 and MDA-MB-231 cells, respectively,

Figure 1: CHK1 inhibitor AZD7762 alone caused more cytotoxicity to RBCC but failed to sensitize RBCC to IR.

(A) Clonogenic survival following IR. Survival experiments were repeated three times and the error bars in the graphs depicting the SD.
Values marked with asterisks are significantly different (T-test, *p < 0.05, **p < 0.01). (B) CHK1 inhibitor (CHK1) failed to sensitize the
MCF-7/C6 cells to IR. The cells were treated with AZD7762 (100 nM), then radiated 1 hr later. 24 hr after IR, the drug was removed from
medium. (C) CHK1 inhibitor AZD7762 alone has more cytotoxicity to MCF-7/C6 cells compared to its own parental cells. Error bars
represent the SD of three independent experiments (T-test, *p < 0.05, **p < 0.01). (D–F) CHK1 inhibitor AZD7762 alone induce more
cytotoxicity in MDA-MB-231 FIR cells but AZD7762 failed to sensitize MDA-MB-231 FIR to IR. The methods and statistical analysis
are the same as described in A–C. (G) Athymic nude mice bearing established MCF-7 or MCF-7/C6 tumors were treated with AZD7762
(25 mg/kg) 2 cycles of therapy 3 days a week (arrows). AZD7762 treatment led to the tumor growth delay with MCF-7/C6 xenografts
relative to tumors without treatment (T-test, p < 0.001).
www.impactjournals.com/oncotarget
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although the magnitude of induction varies (Figure 2A).
This result suggests that oncogenic pathways are induced
in RBCC.
In support of this hypothesis, we found increased
level of RS in RBCC via measurement of single strand
DNA (ssDNA) using bromodeoxyuridine (BrdU) labelling
(Figure 2B, Figure S3A). This assay is based on the
observation that the nucleotide base analogue BrdU is
recognized by an anti-BrdU antibody when incorporated
into ssDNA but not DSBs [36, 37]. In response to RS,
DSBs are often generated due to replication fork collapse.
Correspondingly, we observed an increase in the proportion of
cells positive for γ-H2AX foci, a marker of DSBs, in MCF-7/
C6 cells, compared to MCF-7 cells (Figure 2C, Figure S3B).
To further verify that the increased γ-H2AX foci result from
an accumulation of DSBs not ssDNA, we next performed
comet assay under neutral conditions, which detects DSBs

and not ssDNA [38]. Olive tail moment is increased in MCF7/C6 cells compared to MCF-7 cells (p < 0.05) (Figure 2D),
indicating that RBCC exhibit accumulation of DNA DSBs.
Yet, RBCC are able to proliferate in vitro and form tumors
in vivo, suggesting that these cells have mechanisms in place
to cope with RS. In support of the hypothesis that CHK1
is part of the coping mechanism that inhibits oncogeneinduced replication stress, the expression of ATR/ CHK1
were elevated in MCF-7/C6 and MDA-MB-231 FIR cells
compared to parental cells (Figure 2E). In addition, the
increased expression of HR proteins BRCA1 and CtIP were
also observed in RBCC (Figure 2E). These results described
in Figure 2 suggested that the oncogenes c-Myc/CDC25A/cSrc/H-Ras/E2F1 that can cause replication stress and the
DDR proteins ATR/ CHK1/BRCA1/CtIP that can promote
HR are highly expressed in RBCC. In addition, basal level of
RS increased in RBCC cells.

Figure 2: Increased expression of oncogenes and elevated RS in RBCC. (A) The oncogenes c-Myc/Cdc25A/c-Src/H-ras/

E2F1 were induced in RBCC. (B) Higher levels of ssDNA accumulation in RBCC. The protocol for ssDNA detection has been
described in previous publications [36, 37]. In brief, the cells were grown in the presence of bromodeoxyuridine (BrdU; 10 μg/ml;
Invitrogen) for 24 h. After fixation, the cells were blocked and stained with anti-BrdU mouse monoclonal antibody clone B44
(BD Biosciences, San Jose, CA) antibody. Then, the samples are incubated with an Alexa Fluor 488-conjugated goat anti-mouse antibody.
Cells were scored positive when 10 nuclear foci were visible. The percentages of cells with BrdU foci are indicated. Error bars indicate SD
from three independent experiments (T-test, **p < 0.01). (C) Higher levels of DSB in RBCC. The percentages of cells with γ-H2AX foci
are indicated. In each experiment, 200 nuclei were counted per time. Error bars indicate SD from three independent experiments (T-test,
**p < 0.01). (D) The neutral comet assay of genomic DNA of cells. The results are from three independent experiments (T-test, *p < 0.05).
(E) Increased expression of ATR/CHK1/BRCA1/CtIP in RBCC.
www.impactjournals.com/oncotarget
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CHK1 inhibition upregulates RS, especially in
RBCC

phosphorylation is a marker of CHK1 activation [39],
which targets CHK1 protein to ubiquitination-dependent
degradation [40]. In summary, we conclude that CHK1
inhibition upregulates RS, especially in RBCC.
Since AZD7762 also inhibit CHK2 activity, we next
determine how CHK1 or CHK2 knockdown affects RS in
RBCC. CHK1 knockdown significantly led to increased
γ-H2AX and RPA2-P foci whereas CHK2 knockdown has
no detectable effect in RBCC (Figure S5A–S5C), arguing
that CHK1 inhibition, instead of CHK2 inhibition by
AZD7762, upregulated the extent of RS. These results were
further confirmed by western blot (Figure S5D). Thus, the
increased levels of RS, evidenced by the accumulation of
DSBs and ssDNA are mainly due to the CHK1 inhibition
rather than CHK2 inhibition.

To determine the extent of RS following CHK1
inhibition, we first analyzed foci of RPA2 and phosphorylated
RPA2 (RPA2-P), the markers for RS in response to
exogenous DNA damage agents by immunofluorescence
staining. A more profound increase in the proportion of cells
with RPA2 and RPA2-P foci was observed in MCF-7/C6
cells compared to MCF-7 cells (Figure 3A, 3B). In support
of the above hypothesis, the more significant increase of
RPA2-P in RBCC cells treated with CHK1 inhibitor was also
confirmed by WB (Figure 3C). In addition, CHK1 inhibition
led to a more significant increase in γ-H2AX levels in
MCF- 7/C6 cells, compared to MCF-7 cells (Figure 3D;
Figure S4 left panel). A similar result was also observed in
MDA-MB-231 FIR and parental cells (Figure 3E, 3F; Figure
S4 right panel). Importantly, CHK1 activity was sufficiently
suppressed in our experiments because treatment with CHK1
inhibitor AZD7762 resulted in an increased CHK1 ser345
phosphorylation and reduced global CHK1 protein levels
(Figure 3D). It has been demonstrated that CHK1 ser345

CHK1 inhibition leads to the more significant
increase in replication initiation in MCF-7/C6
cells
Although the mechanisms by which oncogenes cause
RS are not clear, increased origin firing and subsequent

Figure 3: CHK1 inhibition led to the more significant increase in RS in RBCC. (A) Increased proportion of cells with foci
of RPA2 or phosphorylated RPA2 (RPA2 S4/S8) in MCF-7/C6 cells. Data shown are averages from three independent experiments. Error
bars represent the SD of three independent experiments (T-test, *p < 0.05 , **p < 0.01). (B) Representative foci of RPA2 (left panel)
and RPA2 S4/S8 (right panel) are indicated. (C) Expression of RPA2 S4/S8. β-actin or RPA2 are used as loading controls (bottom row).
(D) Accumulation of DSBs in MCF-7/C6 cells. The measurement of γ-H2AX by immunoblotting using an antibody raised against ser139
phosphorylated of H2AX. The inhibition of CHK1 activity was monitored by the measurement of p-CHK1-345 and p-CHK1-317. (E–F)
CHK1 inhibition led to the more significant increase in RPA2 S4/S8 and there is a space γ-H2AX in MDA-MB-231 FIR cells, compared
to control cells.
www.impactjournals.com/oncotarget
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nucleoid scarcity are critical reasons in current models [41].
If CHK1 inhibition abrogates the suppression of oncogenic
stress, thus increased replication initiation should be
observed, especially in radioresistant cells. In order to test
our hypothesis, we first determined how CHK1 inhibitor
affects DNA replication initiation by analyzing DNA fiber
spreads. Cells were sequentially pulse-labeled with IdU and
CldU for 40 min each, according to the protocol illustrated
in Figure 4A. AZD7762 was added to the cell cultures
during the CIdU pulse. IdU and CldU were detected with
specific antibodies, in green and red, respectively. Origins
of replication that were activated prior to the CldU pulse
generated two bidirectional forks, each appearing as a green/
red or red/green signal (Figure 4B, signal a). Conversely,
new origins that fired during the CldU pulse resulted in a
green signal only (Figure 4B, signal b). We quantified the
frequency of new origins in untreated and AZD7762-treated
cells by dividing the number of green signals (b) by the
sum of the green and green/red signals (a + b) (Figure 4B).
The percentage of new origins increased when cells were
treated with AZD7762 in both parental and MCF-7/C6 cells
(Figure 4C), consistent with previous reports that ATR/
CHK1 inhibition or depletion increase origin firing in

unperturbed cells [42, 43]. However, the magnitude of
increase was more significant in MCF-7/C6, compared to
parental cells, indicating that CHK1 inhibitor especially
targets RBCC.
CHK1 is involved in controlling replication initiation
via regulating Cdc45 [44], a protein that is implicated in
initiation rather than elongation processes. We next measured
the amount of Cdc45 in non-extractable chromatin fraction.
AZD7762 treatment caused a remarkable increase in the
amount of non-extractable Cdc45 protein in MCF-7/C6
cells, compared to MCF-7 cells (Figure 4D). This difference
could not be accounted by the differences in Cdc45 levels,
which were comparable in the two cell lines (Figure 4D).
The effect of CHK1 inhibition on chromatin loading of
Cdc45 was further confirmed by IF assay (Figure 4E, 4F).
Moreover, Cdk inhibitor Ro3306 treatment abrogated the
effect of CHK1 inhibitor on Cdc45 chromatin loading
(Figure 4G), which is consistent with a previous report that
CHK1 activity on replication initiation is mediated by Cdk
activity [13]. Last, Cdk inhibition by Ro3306 prevented
accumulation of γ-H2AX and RPA2-P in response
to CHK1 inhibitor AZD7762 in RBCC (Figure 4G),
suggesting that the increased initiation of DNA replication

Figure 4: CHK1 inhibition led to the more profound increase in replication initiation in MCF-7/C6 cells. (A) Schematic
of DNA fiber analysis. Green tracks, CldU; red tracks, IdU. (B) Schematic drawing and representative images of two replication signals
from DNA fibers. At the top, two DNA replication forks moved bidirectionally from an origin (indicated by the diverging black arrows) that
was activated before the CIdU pulse. Each fork was labeled with both IdU (red) and CldU (green). At the bottom, the replication bubble
resulting from an origin that was activated during the CldU pulse produces a green-only signal. (C) Summary of new origins fired during
labeling with CldU. The frequency (as a percentage) was calculated as the number of green signals (b in panel B) divided by the total
(a + b) of green (b) plus green/red signals (a in panel B). Results are from three independent experiment results (T-test, *p < 0.05,
**p < 0.01 ). (D) CHK1 inhibition led to increased levels of nonextractable Cdc45 protein in MCF-7/C6 cells. The cells treated with AZD7762
(100 nM) for the indicated time were incubated with extraction buffer for 5 min on ice, and processed for Western blotting (top panel).
The whole lysate protein is used as a control (bottom panel). (E) Measurement of Cdc45 chromatin loading after preextraction of cells
with detergent by immunostaining. Cells presenting with Cdc45 staining were considered positive. The results are from three independent
experiments. Error bars represent the SD of three independent experiments (T-test, **p < 0.01). (F) Representative Cdc45 staining (green)
in MCF-7 and MCF-7/C6 cells are presented. Cell nuclei were stained with DAPI (blue). (G)The effect of CHK1 inhibition on RS in RBCC
depends on Cdk activity. Cdk activity was inhibited by inhibitor Ro3306.
www.impactjournals.com/oncotarget
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likely contributes to DSBs generation seen after CHK1
inhibition in radioresistant breast cancer cells. Cumulatively,
the results presented in Figure 5 suggest that CHK1
inhibition leads to a significant increase in Cdc45-mediated
replication initiation in RBCC.

replication fork progression by controlling replication origin
activity [14]. Although it is not known how the increased
origin firing could lead to slow replication fork progression,
the imbalance in dNTP pools can cause dysfunctional
replication [46, 47]. Thus, we next determined dATP levels
by Liquid chromatography-tandem mass spectrometry
(LC-MS/MS). Indeed, dATP levels was reduced by 60%
following CHK1 inhibitor treatment in MCF-7/C6 cells
which is significantly higher than the 36% reduction
seen in MCF-7 cells (Figure 5C), indicating that CHK1
inhibition led to the increased deoxynucleotide consumption,
especially in RBCC. Interestingly, a similar phenotype
was found in MDA-MB-231 pairs (Figure 5D–5F), but
with some differences. CHK1 inhibition has an equivalent
effect on replication initiation (Figure 5D) and fork speed
(Figure 5E) in parental MDA-MB-231 and radioresistant
MDA-MB-231 FIR cells. However, CHK1 inhibition failed
to cause scarcity of dNTP pool in both MDA-MB-231 and
MDA-MB-231 FIR cells (Figure 5F). These results suggest
that the increased replication firing may not necessarily lead
to depletion of dNTP pool in all types of tumor cells, and
also that the mechanisms by which CHK1 inhibition leads
to increased levels of RS may be not be limited to regulation
in replication initiation and nucleotide pool balance.

CHK1 inhibition leads to a significant decrease
in replication fork speed and deoxynucleotide
supply in RBCC
Using DNA fiber assay, we next determined how
CHK1 inhibition affects replication fork speed in parental
and radioresistant cells. We predicted that CHK1 inhibition
would reduce replication fork speed due to the increasing
origin firing [45]. The significant decrease in the speed of
replication fork progress was observed in both MCF-7 and
MCF-7/C6 cells when CHK1 activity is inhibited (Figure
5A, 5B). However, the magnitude of the decrease is more
significant in MCF-7/C6 cells compared to MCF-7 cells
(Figure 5A). These results show that CHK1 inhibition
slows down fork progression while increasing origin firing
(replication initiation) in breast cancer cells, and that the
effect is more robust in RBCC (Figure 5A, 5B). These data
are also consistent with the report that CHK1 promotes

Figure 5: CHK1 inhibition led to the more significant decrease in replication speed and deoxynucleotide supply in
MCF-7/C6 cells. (A) A more significant decrease of replication fork speeds in MCF-7/C6, compared to parental MCF-7 cells following

100 nM AZD7762 treatment. Schematic of DNA fiber analysis is the same as described in Figure 5A. The IdU/CIdU ratio was used to
determine elongation. Means and standard deviation (S.D.) of three independent experiments are shown. Values marked with asterisks are
significantly different (T-test, *p < 0.05, **p < 0.01). (B) Representative images of replication tracks from cells treated with or without
AZD7762 (100 nm). (C) Quantitative determination of ATP and dATP in cell lysates was conducted by LC-MS/MS method. Y axis
represents the ratio of dATP/ATP. The details see material and method (T-test, **p < 0.01 , ***p < 0.001). (D–F) CHK1 inhibition had a
similar effect on replication dynamics and deoxynucleotide supply in MDA-MB-231 and MDA-MB-231 FIR cells. (D) Summary of new
origins fired during labeling with CldU. (E) Replication track length analyzed by DNA fiber spreading. Means and standard deviation (S.D.)
The graph is the average of three independent experiments (T-test, **p < 0.01). (F) Quantitative determination of ATP and dATP in MDAMB-231 and MDA-MB-231 FIR cells (NS, no significant difference).
www.impactjournals.com/oncotarget
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CHK1 inhibition leads to more significant
decrease in HR activity in RBCC

the increased expression of ATR/CHK1/BRCA1/CtIP since
these proteins are important for HR activity [20, 21, 52, 53].
The increased HR activity was not caused by the alteration
of the cell cycle because identical cell cycle profiles were
observed in radioresistant cells and their corresponding
parental cells (Figure 6B). We found that CHK1 inhibition
leads to a more significant decrease in HR in RBCC,
compared to parental cells. Collectively, these data suggest
that CHK1 inhibition results in a significant decrease in HR
activity, particular in RBCC cells. This result is consistent
with the observation that CHK1 inhibition led to a more
profound increase in RS in RBCC (Figure 3). Thus, RBCC
cells most likely depend on HR activity for survival
because HR is a major mechanism counteracting the DNA
damage caused by RS.

In addition to interruption of replication dynamics,
CHK1 inhibition may also impair HR. HR is a mechanism
that suppresses RS induced by oncogenes, by promoting
the repair of DSBs that result from replication fork
collapse. Thus, we next determine the role of CHK1
inhibitor in HR activity in both parental and RBCC by HR
reporter DR-GFP as described previously [36, 48–51]. In
this system, a DSB is generated by expressing the I-SceI
endonuclease. Repair of the cleaved I-SceI site by gene
conversion-associated HR gives rise to a functional GFP
gene when the template used for repair is a truncated GFP
fragment located downstream in the plasmid. HR activity
is measured by flow cytometric analysis of the number of
GFP+ cells following I-SceI expression [51]. The parental
MCF-7 cells and MCF-7/C6 cells with chromosome
integration of DR-GFP were established using a standard
method [50]. Using the established system, an increased
frequency of HR in MCF-7/C6 and MDA-MB-231 FIR
cells was observed, compared to their own parental cells
(Figure 6A). The increased HR in RBCC co-related with

DISCUSSION
Chemotherapeutic drugs that as single agents can
specifically target radioresistant cancer cells are rarely
reported and studied although continuing efforts have
been conducted to identify radiosensitizing agents that
preferentially sensitize tumor cells to the cytotoxic action

Figure 6: CHK1 inhibition resulted in a more significant decrease in HR in RBCC. (A) AZD7762 exposure led to decreased

HR-mediated repair, particularly in RBCC. HR was detected using chromosomally integrated HR substrate (DR-GFP) which is based on
reconstitution of the EGFP (from M. Jasin). HR induced by I-SceI was measured by dual-color flow cytometric detection of GFP-positive
cells. In brief, the cells were transfected with I-SceI and then AZD7762 (100 nM) was added to the medium 24 hr after transfection. HR was
measured 24 hr after the addition of AZD7762. Error bars represent the SD of three independent experiments (T-test, *p < 0.05 , **p < 0.01 ,
***p < 0.001). (B) Cell cycle profiles are indicated. Cell cycle was analyzed by flow cytometry. Results are means from three independent
experiments. Error bars represent the SD of three independent experiments (NS, no significant difference).
www.impactjournals.com/oncotarget

34695

Oncotarget

of RT. In contrast to the common paradigm that CHK1
inhibitor can be used as a radiosensitizer, in this study
we report that CHK1 inhibitor, as a single agent, can
specifically target RBCC via regulation of RS (Figure 7),
reducing the growth of tumor cells in vitro and in vivo. Thus,
CHK1 inhibition may provide therapeutic opportunities in
the radioresistant breast cancer patients.

the case, the induced oncogene expression developed during
RT could be toxic to cells due to RS increase. However,
the increased ATR/CHK1/BRCA1/CtIP expression may
constitute a key step to enhance cellular tolerance to
oncogenic stress, considering their roles in suppression of
abnormal replication initiation and promotion of HR, which
are two important mechanisms suppressing oncogenic stress
[12, 22]. Therefore, radioresistant cells are selected because
they confer a growth advantage by overcoming the toxicity
of oncogenic stress via enhancing DDR protein expression
during RT therapy.
Currently, considerations for radiotherapy are
determined by the clinical factors rather than molecular
subtypes and pathways, which might result in the
unnecessary treatment for the patients who are intrinsically
resistant to IR. Whether higher expression of oncogene
proteins c-Myc/CDC25A/c-Src/H-ras/E2F1 and DDR
proteins ATR/CHK1/BRCA1/CTIP can be used as indicators
for the predication of radioresistance need to be determined
in the clinic in the future.

Oncogene proteins and DDR proteins are
induced in RBCC
Oncogenes c-Myc/CDC25A/c-Src/H-Ras/E2F1 and
DDR proteins ATR/CHK1/BRCA1/CtIP are also highly
expressed in RBCC (Figure 2). The physiological
significance of the increase in the expression of both
oncogene proteins and DDR proteins in RBCC is not fully
understood. However, according to the oncogene-induced
DNA damage model of cancer progression [2, 3], oncogenes
generate substantial amounts of RS, which in turn activate
the DDR. Activation of DDR is important to limit the
expansion of tumor cells with RS [54–56], since RS causes
the genomic instability that facilitates the acquisition of
secondary hits in the genome that promote malignancy. To
minimize the impact of this effect and to maintain the fitness
of the cell, the activation of oncogenes is often associated
with compensatory molecular changes, processes mediated
in part by the ATM and ATR protein kinases [19]. If this is

Induced essentiality and targeting RBCC by
CHK1 inhibitor
Several concepts originated in genetics have been
applied to cancer therapy. “Synthetic lethality” describes the
situation where a defect in one gene or protein is compatible

Figure 7: A proposed model for targeting RBCC cells by CHK1 inhibitor via abrogating the suppression in RS induced
by oncogenes. (A) The RBCC express high levels of DDR proteins and oncogene proteins, including ATR/CHK1/BRCA1/CtIP and

c-Myc/CDC25A/c-Src/H-ras/E2F1. The increased expression of DDR protein would be an important mechanism suppressing oncogenic
stress by inhibiting aberrant replication initiation and promoting HR. Therefore, the damages caused by oncogenic stress in RBCC are
minimal and the RBCC with high levels of expression of oncogene proteins survive. (B) CHK1 inhibition enhances oncogenic stress by
abrogating the suppression of replication initiation and/or interrupting HR activity, which leads to the accumulation of massive ssDNA/
DSBs and subsequent death of RBCC.
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with cell viability but results in cell death when combined
(synthesized) with another gene or protein defect. This
concept has been practically applied for the treatment of
breast cancer patients that are defective in BRCA1/2 with
PARP inhibitors [57, 58]. “Induced essentiality” is an
extension of synthetic lethality [59] that refers to a new
state in which mutation of a gene drives the tumorigenic
phenotype of the cells but also has potentially deleterious
effects on cell fitness. Activity of a second gene mitigates
the deleterious effects of the mutation of the first gene.
Thus, the second gene/protein is essential for cell survival.
We speculate that the increased DDR protein expression is
important for the survival of radioresistant cells where the
oncogenes are highly expressed. It is noteworthy that in
our study we observed a more effective antitumor activity
by CHK1 inhibition in RBCC where the oncogenes are
highly expressed (Figures 1, 2). Therefore, it is possible that
targeting radioresistant cancer cells with CHK1 inhibitor
is an extension of the concept of “Induced Essentiality”
to cancer therapy. In support of this concept, ATR/
CHK1 pathway inhibition in combination with oncogene
expression of H-rasG12V cells elevate H2AX phosphorylation
to significantly higher levels than produced in control cells
[55], and also ATR/CHK1 inhibitors are highly effective in
killing Myc-driven lymphomas [56]. Thus, the greatest effect
of CHK1 inhibition in cancer treatment may be achieved in
different types of cancer cells with similar characteristic as
RBCC, based on the same logic. This hypothesis needs to be
intensively tested in future.
Several potential mechanisms could contribute to this
specific targeting of RBCC by CHK1 inhibitor. First, the
radioresistant cells may rely on ATR/CHK1/BRCA1/CTIP
for survival in the absence of exogenous DNA damage due
to their critical role in inhibition of replication initiation and/
or HR promotion as we discussed above. Second, one of
the major differences between radioresistant and parental
cells is that RBCC carry a high level of RS (Figure 2).
The additional DNA damage, as a result of the increased
replication initiation by CHK1 inhibition, may saturate the
DSBs repair ability. Under conditions of proficient DNA
repair, both radioresistant and parental cells may be able
to accomplish full repair. However, if HR is inhibited, the
radio-resistant cell’s additional burden of lesions saturates
the DNA repair capacity and specifically sensitizes the
tumor cells relative to the normal. The increased burden of
DNA DSBs and the impaired HR due to CHK1 inhibition
provide a synthetic lethal interaction that would be selective
for RBCC. These differences between parental and RBCC
provide a unique opportunity to target RBCC.
The radiosensitization activity of CHK1 inhibitor
was observed in previous studies [23, 24, 28], perhaps due
to the interruption of G2/M arrest and HR activity [28].
In our study, CHK1 inhibitor failed to sensitize RBCC to
IR although HR activity and G2/M arrest in RBCC are
abrogated by CHK1 inhibitor (Figure 6, data not shown).
These results suggest that the defects on HR and G2/M
arrest may not necessarily sensitize RBCC to IR. This result
www.impactjournals.com/oncotarget

is consistent with the fact that G2/M phase checkpoint plays
a minimal role in radio sensitivity [60]. In addition, HR is
less important than Non-homologous end joining (NHEJ)
for repair of IR-induced DSBs, although this pathway is
critical for the repair of DSBs that originate during DNA
replication in S phase cells. Thus, it is most likely that
regardless of the impairment of HR and G2/M arrest caused
by CHK1 inhibition, NHEJ pathway can be still active or
upregulated in RBCC cells, which could sufficiently repair
DSBs induced by IR. In support of this hypothesis, NHEJ
activity is significantly higher in RBCC, compared to
parental cells (data not shown). Thus, multiple mechanisms
contribute to the radioresistance of RBCC. Blockage of HR
and G2/M arrest by CHK1 inhibitor are not sufficient to
sensitize these cells to IR.

CHK1 inhibition increases RS levels in RBCC
Our results suggest that CHK1 inhibitor targets RBCC
via regulation of RS caused by oncogenes (Figure 3). The
mechanisms by which oncogenes induce RS have not been
clearly defined. According to a current model, oncogeneinduced RS is a result of hyper-replication, with an increase
in replication initiation and the subsequent scarcity of
replication factors, such as nucleotides [61]. The cellular
availability of nucleotides may not be sufficient to carry
out replication under conditions where a massive number
of origins are fired simultaneously, thus slowing replication
fork. Subsequently, ssDNA and DSBs are induced, and
cell death occurs as a result of massive DNA damage. In
support of our hypothesis that CHK1 inhibitor kills RBCC
via upregulation of oncogenic stress, we find a significant
increase in the firing of replication initiation, a decrease in
dNTP pool, and a reduction in fork progression in MCF-7/C6
cells, in comparison to parental control cells (Figures 4, 5).
However, this may not explain all since CHK1 inhibition
enhances cell killing and replication stress in MDA-MB-231
FIR cells compared to MDA-MB-231 cells. However, the
effect of CHK1 inhibitor on replication initiation/fork
speed and dATP pool is similar in MDA-MB-231 FIR and
MDA-MB-231 cells. Since HR activity is also an important
mechanism suppressing oncogenic stress the effect of CHK1
inhibition in HR activity may contribute to the specific
killing of MDA-MB-231 FIR cells (Figure 6). In our study,
only limited oncogene expression was detected (Figure 2A).
Given that different oncogenes cause RS via distinct
mechanisms, it could be possible that the effect of CHK1
inhibition on replication initiation might depend upon the
context of tumor cells.
In conclusion, we propose a model in which CHK1
inhibitor can be used to specifically target RBCC. CHK1
specifically limits RS by inhibiting replication initiation
and promoting HR in RBCC. In normal conditions,
RBCC survive even with high levels of induced oncogene
expression during RT (Figure 7A). However, when CHK1
activity is inhibited, the suppression of replication initiation is
abrogated, which leads to increased amounts of DSBs. On the
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other hand, the decreased HR activity due to CHK1 inhibition
could also result in a failure to repair DSBs (Figure 7B). The
dual roles of CHK1 inhibitor in interruption of replication
initiation and HR contribute to its antitumor activity in RBCC
(Figure 7). In our model, targeting RBCC and upregulating
RS by CHK1 inhibition appears to be independent of p53
since CHK1 inhibition leads to more cell killing and the more
profound increase in RS, compared to their parental cells
regardless of the status of p53 (Figures 1, 3). Our result is
consistent with a recent publication indicating that oncogenic
stress sensitizes murine cancers to hypomorphic suppression
of ATR, and the toxic interaction between ATR suppression
and oncogenic stress occurred independent of p53 status
[54]. However, we cannot exclude the possibility that p53 is
involved to certain extent, because a remarkable cell killing by
CHK1 inhibitor is observed in wild type p53 expressing cells
(MCF-7/C6) in comparison to mutant p53 expressing cells
(MDA-MB-231 FIR) (Figure 1).
In summary, our study reveals that upregulation of
RS could be a promising strategy targeting radioresistant
breast cancer cells by CHK1 inhibition. In addition, it is
conceivable that RBCC or any situations harboring same
characteristics as RBCC may be prime candidates for
treatments utilizing CHK1 inhibition.

5H9, 1:200, GeneTex); anti-RPA2 (Clone NA18, 1:100,
Calbiochem/EMD Millipore); Anti-53BP1(Clone 1B9,
1:1000, Novus biologicals); Anti-E2F1(Clone KH95,
1:200, Santa Cruz Technology); Anti-β-Actin ( Clone AC74, 1:10000, Sigma-Aldrich); Anti Mre11 (1:1000, Novus
Biologicals); Anti-CHK1 (G-4, 1:500, Cell signaling);
Phospho-CHK1 antibody (#2344 CHK1-pSer317,1:500;
Cell signaling); Phospho- CHK1 antibody (#133D3
CHK1-pSer345, 1:500, Cell signaling); Anti c-Myc
(9E10 sc40, 1:300,Cell signal), Anti E2F1 (clone KH95
sc-251, 1:500,Cell signaling); H-ras(F235 sc-29, 1:50,
cell signaling); c-Src(N-16 sc-19, 1:50, cell signaling);
Anti Cdc45 (G-12 sc55569, 1:50, Santa Cruz); γ-H2Ax
(ser139 JBC301, 1:500, Millipore clone); rabbit polyclonal
antibody phosphor RPA32 Ser4/Ser8 (Bethyl, BL647,
1: 1000 dilution), Anti CDC25A (clone DCS-120, 1:100,
Thermo scientific); Cdk2 (610146, 1:200,BD Biosciences);
cyclin E (sc247, 1:200, Santa Cruz Technology) for western
blotting.Secondary antibodies used were goat-anti-mouse
IgG–horseradish peroxidase (HRP) conjugated, goat-antirabbit IgG–HRP conjugated at 1:1000 dilutions. Radiation
was delivered to cultured cells using a cesium-137 gamma
ray at a dose rate of 3.1 Gray /min.

Immunofluorescence analysis

MATERIALS AND METHODS

Mouse anti-γ-H2AX (Ser139, clone JBW301,
millipore) was used at 1:500 dilution. The monoclonal
anti-BrdU antibody (BD Biosciences) was used at 1:200
concentration. Rabbit anti- RPA32 (S4/S8) [A300-245A,
BETHYL] were used at 1:500 dilution. For analysis of
Cdc45 chromatin staining, a detergent extraction method was
employed as described previously (9). Rabbit anti-Cdc45
(H- 300, clone, sc20685, Santa Cruz) was used 1:50 dilution.
The secondary antibody, goat–anti-mouse IgG Alexa fluor
594 or FITC-conjugated anti-mouse secondary antibody
(sigma) was used at 1:400 dilution. The slides were viewed
at 1000 × magnification on an NIKON 90i fluorescence
microscope (photometric cooled mono CCD camera).

Cell lines, infections, transfections and inhibitors
Parental cells and their corresponding radioresistant
derivatives were obtained from JianJian Li (University of
California Davis). MCF-7 and MCF-7/C6 cells were cultured
in Minimum Essential Medium (MEM, lifetechnologies)
supplemented with 10% bovine growth serum, 100 U/ml
penicillin and 100 μg/ml streptomycin at 37°C, 5% CO2.
MDA-MB-231 and MDA-MB-231 FIR cells were cultured
in Dulbecco’s Modified Eagle Medium (DMEM with Low
Glucose, HyClone) supplemented with 10% bovine growth
serum, 100 U/ml penicillin and 100 μg/ml streptomycin
at 37°C, 5% CO2. MCF-7/C6 cells with chromosomal
integration of the DR-GFP reporter were generated according
to a standard protocol. CHK1 and CHK2 short-hairpin
RNAs (shRNA) were purchased from Sigma. All DNA
plasmid transfections were performed using Lipofectamine
2000 according to the manufacturer’s recommendations
(Invitrogen, Carlsbad, CA). The CHK1 inhibitors AZD7762
and LY2603618 were purchased from Selleckchem and
ApexBio, respectively. The Cdk inhibitor Ro3306 was
purchased from Tocris.

Homologous recombination assay
HR was measured in cells according to previous
publications [50].

Cell cycle analysis
Cell Cycle Analysis was conducted as we described
previously [50].

Immunoblotting

Comet assay

The following conditions are used. Anti-BRCA1
(Clone D-9, 1:200, Santa Cruz Technology); Anti-RAD51
(Clone H92; 1:200; Santa Cruz Technology); Anti-BRCA2
(Clone 5.23, 1:500, EMD Millipore); Anti-RAD52 (Clone

Cells were analyzed by the Comet assay under
neutral conditions (Trevigen, Gaithersburg, MD). Comets
were analyzed using CometScore software (TriTek,
Sumerduck, VA).
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Colony formation assay

for the Care and Use Of Laboratory Animal Resource,
(1996) National Research Council. For tumor growth delay
studies, Implant the 17β-ESTRADIOL(innovative research
of America cat#NE-121 0.72 mg/pellet 90-day release) into
the mice on the neck one week prior to cells injection, then
8 × 106 cells were suspended and then injected subcutaneously
into flanks. Tumor growth was followed until the diameter
of tumor reached 0.6–0.8 cm. At this point animals were
randomized into 2 groups (8 mice/group): control and
AZD7762. AZD7762 (25 mg/kg) was administered by i.p.
injection at 2,3,5 days (once a day) as a cycle for 2 cycles.
Students T-test was used to calculate the delay of two group
and p-values for the differences between the various groups.

Clonogenic analysis was performed as described
in reference [50]. Colonies containing > 50 cells were
counted.

DNA fiber assay
DNA fiber assay were performed as published
previously [62]. The replication fibers were viewed
at 1000× magnification on an NIKON 90i fluorescence
microscope (photometric cooled mono CCD camera).
Signals were measured by using Image J software (NCI/
NIH), with some modifications made specifically to measure
DNA fibers.
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The cells (1 × 107) were suspended in 0.5 ml of 80%
methanol aqueous solution. The mixture went through a
process of freezing (−80°C) and thawing (room temperature)
for 3 times, followed by a sonication for 10 min, and then
centrifuged. The supernatant was dried with N2. The residue
was dissolved in 400 μl of 10 mM ammonium formate
solution, and 100 μl of the solution was used for LC-MS
analysis. The separation of analytes was carried out on an
XTerra C18 column (2.1 × 100 mm) using a gradient elution
from 20% B to 80% B in 12 min at a flow rate of 0.2 ml/min.
The mobile phase A was 1 mM tributylamine and 0.25
mM acetic acid aqueous solution, and mobile phase B was
90% methanol with 1 mM tributylamine and 0.25 mM
acetic acid. All calibrators, internal standards (ATP-d4
and dATP-13C10,15N5), and QC samples were prepared
in 10 mM ammonium formate solution. 10 μl of samples
was injected. This method has a linear calibration range of
5.00–500 ng/ ml for dATP and 100–50000 ng/ml for ATP.
The API 3200 mass spectrometer was operated using ESI– .
Quantitation was done by MRM mode with the following
parameters: m/z 506 > 273 for ATP, m/z 510 > 159 for
ATP-d4, m/z 490 > 159 for dATP, m/z 505 > 159 for dATP13C10,15N5, dwell time at 50 ms, declustering potential
(DP) at −53 V, entrance potential (EP) at −6.0 V, collision
energy (CE) at −30 V, collision cell exit potential (CXP)
at −6.0 V, curtain gas (CUR) at 25, collision gas (CAD) at
3, ionspray voltage (IS) at −4500V, temperature (TEM) at
600°C, ion source gas 1 (GS1) at 50, ion source gas 2 (GS2)
at 50, and resolutions were set at unit for both Q1 and Q3.
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